Our cells use messenger RNA (mRNA) to translate DNA (genes) into proteins which are required for the healthy function of the human body. Expression of disease-relevant proteins can be achieved by molecular targeting of a specific gene through mRNA. ValamAi's technology aims to use mRNA to direct a patient's cells to manufacture their own functional proteins and help the body heal itself to protect against disease.
ValamAi has discovered and developed ways to optimize protein production and secretion through employing modifications in mRNA coding information, thereby controlling the translation and processing of disease-related proteins. Its platform technology offers the potential to produce several new molecular entities that show different tissue specificity for one therapeutic target. This ensures the full exploration of its therapeutic value in different tissues and hence disease areas.
The multi-protein platform focuses on RNA molecules that simultaneously target more than one therapeutic protein, thereby up- and/or down-regulating these proteins independently. With the multi-protein platform, ValamAi is capable of applying linked and synergistic therapeutic concepts — e.g. immunomodulatory, anti-inflammatory and pro-regenerative mechanisms — within one drug candidate.
Given the immense potential of combinatory therapeutic approaches, ValamAi is exploring oncology to validate its multi-protein platform in cancer therapies. The team is applying the combinatory approach to target scientifically established mechanisms associated with cancer progression, metastasis or chemoresistance in one therapeutic molecule. The biological mechanisms targeted by these molecules are expected to apply to multiple tumor types.
Topical treatment is strongly preferred over systemic therapy in dermatology, yet topical formulations have historically been limited to small molecules — leaving roughly 85–90% of proteins undruggable by classical small-molecule approaches. ValamAi is extending its mRNA platform into a topical RNA cream format, opening up precision dermatology targets such as androgenetic alopecia, acne, melasma, wrinkles, psoriasis, atopic dermatitis and vitiligo that are otherwise difficult to reach.
RNA therapies make every target druggable. Combining RNA with topical formulation and cosmetics-adjacent applications is a novel, largely uncontested niche for ValamAi, with the potential for reduced regulatory hurdles relative to systemic RNA therapies.
